L.V.A.M. Beex
About
L.V.A.M. Beex is a scholar working on Oncology, Cancer Research and Genetics.
According to data from OpenAlex, L.V.A.M. Beex has authored 96 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Oncology, 47 papers in Cancer Research and 41 papers in Genetics. Recurrent topics in L.V.A.M. Beex's work include Breast Cancer Treatment Studies (35 papers), Estrogen and related hormone effects (31 papers) and HER2/EGFR in Cancer Research (14 papers). L.V.A.M. Beex is often cited by papers focused on Breast Cancer Treatment Studies (35 papers), Estrogen and related hormone effects (31 papers) and HER2/EGFR in Cancer Research (14 papers). L.V.A.M. Beex collaborates with scholars based in Netherlands, Belgium and United States. L.V.A.M. Beex's co-authors include Fred C.G.J. Sweep, Peggy Manders, Paul N. Span, M. Nooij, C. Boetes, Jan G.M. Klijn, Vivianne C. G. Tjan‐Heijnen, Hans Peterse, Jan C. Oosterwijk and Emiel J. Rutgers and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.
In The Last Decade
L.V.A.M. Beex
96 papers receiving 5.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| L.V.A.M. Beex Netherlands | 38 | 2.6k | 2.2k | 1.6k | 1.1k | 1.1k | 96 | 5.6k | ||
| Tommy� Fornander Sweden | 45 | 2.9k 1.1× | 2.6k 1.2× | 2.1k 1.3× | 1.2k 1.1× | 1.2k 1.1× | 133 | 6.5k | ||
| C. Kent Osborne United States | 42 | 3.8k 1.5× | 2.4k 1.1× | 2.9k 1.8× | 2.8k 2.5× | 1.0k 0.9× | 104 | 7.4k | ||
| C. Kent Osborne United States | 33 | 2.9k 1.1× | 2.1k 1.0× | 1.8k 1.1× | 2.2k 1.9× | 743 0.7× | 82 | 5.6k | ||
| Jacques Bonneterre France | 44 | 5.1k 2.0× | 2.8k 1.3× | 1.5k 0.9× | 1.9k 1.7× | 1.7k 1.5× | 257 | 8.0k | ||
| Diana Crivellari Italy | 37 | 3.3k 1.3× | 2.1k 0.9× | 681 0.4× | 694 0.6× | 1.2k 1.0× | 152 | 4.9k | ||
| P Sismondi Italy | 47 | 2.7k 1.0× | 1.8k 0.8× | 1.9k 1.2× | 1.7k 1.5× | 834 0.7× | 188 | 6.9k | ||
| Grazia Arpino Italy | 37 | 4.2k 1.6× | 2.8k 1.3× | 1.6k 1.0× | 1.7k 1.5× | 1.6k 1.4× | 157 | 6.7k | ||
| J.G.M. Klijn Netherlands | 43 | 3.5k 1.3× | 2.9k 1.3× | 3.2k 2.0× | 2.4k 2.1× | 725 0.6× | 116 | 7.9k | ||
| Thomas Hatschek Sweden | 29 | 2.4k 0.9× | 1.9k 0.9× | 754 0.5× | 1.1k 1.0× | 956 0.8× | 100 | 4.5k | ||
| Rinat Yerushalmi Israel | 27 | 4.4k 1.7× | 2.3k 1.0× | 1.2k 0.7× | 2.2k 2.0× | 1.8k 1.6× | 119 | 6.7k |
Countries citing papers authored by L.V.A.M. Beex
Since
Specialization
Citations
This map shows the geographic impact of L.V.A.M. Beex's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L.V.A.M. Beex with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L.V.A.M. Beex more than expected).
Fields of papers citing papers by L.V.A.M. Beex
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by L.V.A.M. Beex. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L.V.A.M. Beex. The network helps show where L.V.A.M. Beex may publish in the future.
Co-authorship network of co-authors of L.V.A.M. Beex
This figure shows the co-authorship network connecting the top 25 collaborators of L.V.A.M. Beex. A scholar is included among the top collaborators of L.V.A.M. Beex based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L.V.A.M. Beex. L.V.A.M. Beex is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Vos, Filip De, Hanneke W.M. van Laarhoven, Joop S.E. Laven, et al.. (2012). Menopausal status and adjuvant hormonal therapy for breast cancer patients: A practical guideline. Critical Reviews in Oncology/Hematology. 84(2). 252–260.
2.
Nes, Johanna G. H. van, Caroline Seynaeve, E. Maartense, et al.. (2009). Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial. Annals of Oncology. 21(5). 974–982.
3.
Paridaens, Robert, Luc Dirix, L.V.A.M. Beex, et al.. (2008). Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. Journal of Clinical Oncology. 26(30). 4883–4890.
4.
Kolwijck, Eva, Erik A. Boss, Anne M. van Altena, L.V.A.M. Beex, & Leon F.A.G. Massuger. (2007). Stage IV epithelial ovarian carcinoma in an 18 year old patient presenting with a Sister Mary Joseph's nodule and metastasis in both breasts: A case report and review of the literature. Gynecologic Oncology. 107(3). 583–585.
5.
Peer, Petronella G.M., Peter Bult, Erik Thunnissen, et al.. (2006). Risk Factors for Non-Sentinel Lymph Node Metastases in Patients with Breast Cancer. The Outcome of a Multi-institutional Study. Annals of Surgical Oncology. 14(1). 181–189.
6.
Kriege, Mieke, Cecile T.M. Brekelmans, C. Boetes, et al.. (2005). Efficacy of Magnetic Resonance Imaging and Mammography for Breast Cancer Screening in Women With a Familial or Genetic Predisposition. Obstetrical & Gynecological Survey. 60(2). 107–109.
7.
Kriege, Mieke, Cecile T.M. Brekelmans, C. Boetes, et al.. (2004). Efficacy of MRI and Mammography for Breast-Cancer Screening in Women with a Familial or Genetic Predisposition. New England Journal of Medicine. 351(5). 427–437.
8.
Paridaens, Robert, Luc Dirix, Caroline Lohrisch, et al.. (2003). Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Annals of Oncology. 14(9). 1391–1398.
9.
Span, Paul N., Fred C.G.J. Sweep, Peggy Manders, et al.. (2003). Matrix metalloproteinase inhibitor reversion‐inducing cysteine‐rich protein with Kazal motifs. Cancer. 97(11). 2710–2715.
10.
Span, Paul N., Vivianne C. G. Tjan‐Heijnen, Peggy Manders, L.V.A.M. Beex, & Fred C.G.J. Sweep. (2003). Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer. Oncogene. 22(31). 4898–4904.
11.
Awada, Ahmad, Laura Biganzoli, Tanja Čufer, et al.. (2002). An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes. European Journal of Cancer. 38(6). 773–778.
12.
Dorssers, Lambert C. J., S. van der Flier, Arend Brinkman, et al.. (2001). Tamoxifen Resistance in Breast Cancer. Drugs. 61(12). 1721–1733.
13.
Hamilton, Anne, J.A. Roy, L.V.A.M. Beex, et al.. (2000). EORTC 10941: A phase II study of liarozole in postmenopausal patients with ‘Chemotherapy-Resistant’ or ‘Potentially Hormone Sensitive’ metastatic breast cancer. Breast Cancer Research and Treatment. 60(2). 181–188.
14.
Barnes, D M, Rosemary R. Millis, L.V.A.M. Beex, S.M. Thorpe, & Robin Leake. (1998). Increased use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: the need for quality assurance. European Journal of Cancer. 34(11). 1677–1682.
15.
Sweep, Fred C.G.J., et al.. (1998). Complexes between urokinase-type plasminogen activator and its receptor in blood as determined by enzyme-linked immunosorbent assay. International Journal of Cancer. 77(2). 236–242.
16.
Vogels, M T, et al.. (1997). Cutaneous infection due to Mycobacterium abscessus. A case report.. Acta Dermato Venereologica. 77(3). 222–224.
17.
Deutman, August F., et al.. (1997). Unusual retinal pigment epitheliopathy and choroidopathy in carcinomatosis: A rare case of cancer-associated retinopathy. Graefe s Archive for Clinical and Experimental Ophthalmology. 235(1). 59–61.
18.
Vasen, Hans F. A., L.V.A.M. Beex, F. J. Cleton, et al.. (1993). Clinical heterogeneity of hereditary breast cancer and its impact on screening protocols: The dutch experience on 24 families under surveillance. European Journal of Cancer. 29(8). 1111–1114.
19.
Koenders, P., et al.. (1992). Human breast cancer: survival from first metastasis. Breast Cancer Research and Treatment. 21(3). 173–180.
20.
Beex, L.V.A.M., Marius MacKenzie, John Raemaekers, et al.. (1988). Adjuvant chemotherapy in premenopausal patients with primary breast cancer; relation to drug-induced amenorrhoea, age and the progesterone receptor status of the tumour. European Journal of Cancer and Clinical Oncology. 24(4). 719–721.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Tommy� Fornander Breakdown of academic impact, for papers by C. Kent Osborne Breakdown of academic impact, for papers by C. Kent Osborne Breakdown of academic impact, for papers by Jacques Bonneterre Breakdown of academic impact, for papers by Diana Crivellari Breakdown of academic impact, for papers by P Sismondi Breakdown of academic impact, for papers by Grazia Arpino Breakdown of academic impact, for papers by J.G.M. Klijn Breakdown of academic impact, for papers by Thomas Hatschek Breakdown of academic impact, for papers by Rinat Yerushalmi